Among the upcoming haematology meeting’s non-oncology presentations Uniqure’s haemophilia B gene therapy scores a valuable late-breaker.
But the Soloist trial suggests a benefit in heart failure with preserved ejection fraction, which might be good news for Lexicon’s SGLT2 rivals.
The full Galactic-HF data were supposed to have suggested a path forward. Instead they point the way to disagreement.
A Keytruda combo trial of the company’s Tavo shows an improving dataset, as remissions appear to deepen with time.
Unveiling of abstracts for December’s haematology meeting sent Crispr up and Allogene down, but the biggest beneficiary was private.
Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Despite the lack of an overall survival benefit the Seal study gives Karyopharm enough to file for Xpovio’s first solid tumour use.
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.